Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 18/20 | 0.44 |
| ▸ | CDK2 | P24941 | 18/20 | 0.44 |
| ▸ | CCND1 | P24385 | 9/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.44 |
| ▸ | CDK4 | P11802 | 6/20 | 0.44 |
| ▸ | CDK9 | P50750 | 6/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23209355 | 0.93 | JAK2 (0.43) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL23209268 | 0.91 | JAK1 (0.45) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL23209308 | 0.90 | CCNE1 (0.45) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL23209223 | 0.89 | JAK1 (0.44) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL23209251 | 0.89 | JAK1 (0.44) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL23209264 | 0.86 | CCNE1 (0.42) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL23209227 | 0.86 | JAK1 (0.49) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL23209335 | 0.86 | WNT1 (0.35) | CCNE1CDK2CDK6CDK4JAK1 | |
| SCHEMBL23209427 | 0.85 | JAK2 (0.48) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL23209357 | 0.85 | JAK2 (0.47) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | claimed |
| CN-115298177-B | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2025-01-17 | — | — | CN | claimed |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-05-30 | — | — | US | claimed |
| CN-115298177-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2022-11-04 | — | — | CN | claimed |
| EP-4041731-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-08-17 | — | — | EP | claimed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | claimed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | claimed |
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | CCNE1 3/4885CDK2 10/4885CCND1 20/4885 |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | CCNE1 35/4885CDK2 1/4885CCND1 59/4885 |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | CCNE1 35/4885CDK2 1/4885CCND1 59/4885 |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | CCNE1 35/4885CDK2 1/4885CCND1 59/4885 |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | CCNE1 35/4885CDK2 1/4885CCND1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.